Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin
Hua Medicine (the "Company", or "Hua Medicine", SEHK stock code: 2552.HK) today announced that at the 6th China BioMed Innovation and Investment Conference (the "CBIIC"), Professor Jianhua MA, Director of the Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society, as one of the principal researchers, presented the results from a clinical study called DREAM, which showed that dorzagliatin, a glucokinase activator and a first-in-class investigational drug of Hua Medicine, may make progress in diabetes remission.